Angina Is as Subjective as Any Other Pain

Almost 80% of all patients randomized in this study reported Canadian Cardiovascular Society class II or III angina, and almost all of them (97%) had more than 1 positive non-invasive ischemia test that matched the area of their single diseased coronary vessel. Beyond fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR), the study randomized patients to undergo angioplasty or a sham procedure (placebo group). We might have expected angioplasty patients to resolve their symptoms and placebo patients to continue with the same angina functional class. It should be noted that all patients were symptomatic and they all had single-vessel disease, with ischemia shown in more than one functional study.

Our expectations turned out to be quite different from reality, since almost half the patients who underwent angioplasty continued with angina and, more interestingly, 31.5% of placebo patients (i.e., those who underwent a sham procedure) reported being symptom-free. That is a significant difference, which leads us to conclude that, while angioplasty does actually improve symptoms, some things we are yet to understand.

 

Before randomization, all patients were assessed with iFR and FFR, while results were blinded. Mean FFR was 0.69 ± 0.16 and mean iFR was 0.76±0.22 (undoubtedly, all subjects were ischemic patients) in 196 study patients, among whom 103 underwent angioplasty and 93 underwent a placebo procedure.


Read also: CTO Revascularization Improves Quality of Life.


Angioplasty clearly improved stress echocardiography scores (p < 0.0001) and its effect was progressively more evident with decreasing FFR and iFR (p for interaction < 0.00001). That is the expectable, logical result for this study.

 

However, angioplasty did not improve angina frequency scores significantly more than placebo, and there was no detectable evidence of interaction with FFR (p = 0.849) or iFR (p = 0.783) results.


Read also: Manual vs. Mechanical Compression after Transradial Catheterization.


Despite all of the above, as it was mentioned at the beginning of this article, angioplasty was associated with more freedom from angina (49.5% versus 31.5%; odds ratio [OR]: 2.47; 95% confidence interval [CI]: 1.30 to 4.72; p = 0.006), although neither FFR nor iFR could predict this effect.

 

This is undoubtedly one of the most interesting studies ever published on ischemic heart disease and, despite its scarce 196 patients, it is certainly bound to start a debate.

 

Original title: Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease. Physiology-Stratified Analysis of ORBITA.

Reference: Al-Lamee R et al. Circulation. 2018 May 22. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...